Chronic obstructive pulmonary disease (
COPD) is an increasingly important cause of morbidity and mortality, pathological features of which are
pulmonary inflammation and irreversible airflow obstruction. Current
therapies for
COPD are aimed at improvement of clinical symptoms and reduction of
inflammation in the respiratory systems. There is a pressing need for the development of new
COPD medication, particularly as no existing treatment has been shown to reduce
disease progression. In spite of a better understanding of the underlying disease process, there have been limited advances in the
drug therapy of
COPD, in contrast to the enormous advances in
asthma management. Several new therapeutic targets and strategies have been proposed, and new drug candidates, including
bronchodilators,
protease inhibitors anti-inflammatory drugs and mediator antagonists, are now in clinical development for
COPD treatment. New
dry powder inhaler (DPI) systems for inhaled
COPD therapy have also been developed to maximize drug concentrations in the airway systems, while minimizing systemic exposure and associated toxicity. This article aims to review recent developments in
COPD drugs and the delivery systems for
inhalation therapy, with particular emphasis on device options and formulations of DPI systems.